Table A2.
Protocols and Treatments for HR Patients With Stage 4 NB at MSKCC
| Immunotherapy Group | Before Immunotherapy |
CRA | No. of Patients | ||
|---|---|---|---|---|---|
| MSKCC Protocol Name | ClinicalTrials.gov | Consolidation | |||
| Regimen A (3F8 alone) | N6 | NCI-V90-0023 | None | None | 19 |
| N7 | NCT00002634 | 131I-3F8 | None | 24 | |
| Regimen B (3F8 + IV GM-CSF + CRA) | 94-018 | NCT00002560 | SCT | Yes | 41* |
| Regimen C (3F8 + SC GM-CSF + CRA) | 03-077 | NCT00072358 | None | Yes | 39 |
| 03-077 | NCT00072358 | SCT | Yes | 46 | |
NOTE. HR patients had stage 4 NB diagnosed at age ≥ 18 months or with MYCN amplification.
Abbreviations: 3F8, anti-GD2 monoclonal antibody 3F8; CRA, 13-cis-retinoic acid; GM-CSF, granulocyte-macrophage colony-stimulating factor; HR, high risk; IV, intravenous; MSKCC, Memorial Sloan-Kettering Cancer Center; NB, neuroblastoma; SC, subcutaneous; SCT, stem-cell transplantation.
*
One patient did not undergo SCT.